Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia

Ming Chih Yu, Jun Hao Chen, Chi Yin Lai, Cheng Ying Han, Wun-Chang Ko

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [3H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic α2-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an α2-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30 μM) competitively inhibited PDE1-5 activities, with Ki values of 15.0, 6.4, 13.9, 11.1, and 9.5 μM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (Kd) and maximal density (Bmax) for [3H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1 nM and 3.7 pmol/g of tissue, respectively. The EC50 (PDE4H) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2 nM [3H]-rolipram binding were 11.2 μM and 45.6 nM, respectively. The therapeutic (PDE4H/PDE4L) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30 μmol/kg, s.c.) and Ro 20-1724 (0.1-1 μmol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4H/PDE4L) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.

Original languageEnglish
Pages (from-to)269-275
Number of pages7
JournalEuropean Journal of Pharmacology
Volume627
Issue number1-3
DOIs
Publication statusPublished - Feb 10 2010

Fingerprint

Rolipram
Xylazine
Luteolin
Phosphodiesterase 5 Inhibitors
Ketamine
Anesthesia
Binding Sites
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
Vomiting
Phosphodiesterase 4 Inhibitors
Ferrets
Adrenergic Receptors
Nausea
Stomach
Clonidine
Chronic Obstructive Pulmonary Disease
Hypersensitivity
Guinea Pigs
Asthma
Cell Membrane

Keywords

  • Emesis
  • High-affinity rolipram binding site
  • Luteolin
  • PDE4/PDE4 ratio
  • Phosphodiesterase (PDE) 1-5 inhibitor
  • Xylazine/ketamine-induced anesthesia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. / Yu, Ming Chih; Chen, Jun Hao; Lai, Chi Yin; Han, Cheng Ying; Ko, Wun-Chang.

In: European Journal of Pharmacology, Vol. 627, No. 1-3, 10.02.2010, p. 269-275.

Research output: Contribution to journalArticle

@article{384ba226d688435fb9340e1718341ad6,
title = "Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia",
abstract = "The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [3H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic α2-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an α2-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30 μM) competitively inhibited PDE1-5 activities, with Ki values of 15.0, 6.4, 13.9, 11.1, and 9.5 μM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (Kd) and maximal density (Bmax) for [3H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1 nM and 3.7 pmol/g of tissue, respectively. The EC50 (PDE4H) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2 nM [3H]-rolipram binding were 11.2 μM and 45.6 nM, respectively. The therapeutic (PDE4H/PDE4L) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30 μmol/kg, s.c.) and Ro 20-1724 (0.1-1 μmol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4H/PDE4L) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.",
keywords = "Emesis, High-affinity rolipram binding site, Luteolin, PDE4/PDE4 ratio, Phosphodiesterase (PDE) 1-5 inhibitor, Xylazine/ketamine-induced anesthesia",
author = "Yu, {Ming Chih} and Chen, {Jun Hao} and Lai, {Chi Yin} and Han, {Cheng Ying} and Wun-Chang Ko",
year = "2010",
month = "2",
day = "10",
doi = "10.1016/j.ejphar.2009.10.031",
language = "English",
volume = "627",
pages = "269--275",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia

AU - Yu, Ming Chih

AU - Chen, Jun Hao

AU - Lai, Chi Yin

AU - Han, Cheng Ying

AU - Ko, Wun-Chang

PY - 2010/2/10

Y1 - 2010/2/10

N2 - The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [3H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic α2-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an α2-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30 μM) competitively inhibited PDE1-5 activities, with Ki values of 15.0, 6.4, 13.9, 11.1, and 9.5 μM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (Kd) and maximal density (Bmax) for [3H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1 nM and 3.7 pmol/g of tissue, respectively. The EC50 (PDE4H) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2 nM [3H]-rolipram binding were 11.2 μM and 45.6 nM, respectively. The therapeutic (PDE4H/PDE4L) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30 μmol/kg, s.c.) and Ro 20-1724 (0.1-1 μmol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4H/PDE4L) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.

AB - The aim of the present study was to investigate the mode of action of luteolin on phisphodiesterase (PDE) 1-5, and the possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [3H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia. The reversing effect was reported to occur through a presynaptic α2-adrenoceptor inhibition and trigger vomiting in ferrets. In contrast, clonidine, an α2-adrenoceptor agonist, prevented emesis induced by PDE4 inhibitors in ferrets. According to the Lineweaver-Burk analysis, luteolin (3-30 μM) competitively inhibited PDE1-5 activities, with Ki values of 15.0, 6.4, 13.9, 11.1, and 9.5 μM, respectively, which did not significantly differ from each other. The equilibrium dissociation constant (Kd) and maximal density (Bmax) for [3H]-rolipram binding at high-affinity rolipram binding sites of guinea pig brain cell membranes were 10.1 nM and 3.7 pmol/g of tissue, respectively. The EC50 (PDE4H) values of luteolin and Ro 20-1724, a selective PDE4 inhibitor, for displacing 2 nM [3H]-rolipram binding were 11.2 μM and 45.6 nM, respectively. The therapeutic (PDE4H/PDE4L) ratios of luteolin and Ro 20-1724 were calculated to be 0.6, and 0.004, respectively. Both luteolin (10-30 μmol/kg, s.c.) and Ro 20-1724 (0.1-1 μmol/kg, s.c.) significantly reversed the xylazine/ketamine-induced anesthesia in mice. Although luteolin non-selectively and competitively inhibited PDE1-5, only PDE4 inhibition contributed to a reversing effect. In conclusion, because of the low therapeutic (PDE4H/PDE4L) ratio of luteolin, the gastrointestinal adverse effects such as nausea, vomiting and gastric hypersecretion should be carefully monitored, whenever luteolin is used for treating allergies, asthma or chronic obstructive pulmonary disease.

KW - Emesis

KW - High-affinity rolipram binding site

KW - Luteolin

KW - PDE4/PDE4 ratio

KW - Phosphodiesterase (PDE) 1-5 inhibitor

KW - Xylazine/ketamine-induced anesthesia

UR - http://www.scopus.com/inward/record.url?scp=73449123347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73449123347&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2009.10.031

DO - 10.1016/j.ejphar.2009.10.031

M3 - Article

C2 - 19853596

AN - SCOPUS:73449123347

VL - 627

SP - 269

EP - 275

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -